January 9, 2025 | NEJM
Image Challenge from the New England Journal of Medicine — January 9, 2025
Related Articles
The Plight of “Dual Noneligible” People in the United States | NEJM
Policy solutions are needed to cover adequate health care for the approximately 1.1 million older, low-income adults in the United States who are undocumented immigrants.
Recombinant Influenza Vaccine Elicits Improved, Sustained Immune Response
Recombinant influenza vs standard dose inactivated influenza vaccines elicited more robust humoral immune responses at 1- and 6-months postvaccination.
A Comparison of Peripherally Inserted Central Catheter Materials | NEJM
New catheter materials for peripherally inserted central catheters (PICCs) may reduce the risk of device failure due to infectious, thrombotic, and catheter occlusion events. However,…
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma | NEJM
Talquetamab (anti–G protein–coupled receptor family C group 5 member D) and teclistamab (anti–B-cell maturation antigen) are bispecific antibodies that activate T cells by targeting CD3…
See the Harm | NEJM
Medical students are faced with a dilemma: for them to learn, enough people have to get sick, with varied and sometimes terrible illnesses. In order…
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma | NEJM
Twelve hundred ninety-six patients with resected colon cancer that either was locally invasive (Stage B2) or had regional nodal involvement (Stage C) were randomly assigned…
Heart Failure with Preserved Ejection Fraction | NEJM
Heart failure with preserved ejection fraction is noted for symptoms of heart failure, LVEF of at least 50%, and cardiac or structural abnormalities. Treatment includes…
NEJM Notable Articles 2024
The store will not work correctly when cookies are disabled. Discover the 14 articles NEJM editors selected as the most impactful in advancing clinical practice…
Omalizumab for the Treatment of Multiple Food Allergies | NEJM
Original Article from The New England Journal of Medicine — Omalizumab for the Treatment of Multiple Food Allergies